Facebook Pixel {العنوان: سلسلة} | {اسم المغناطيس: سلسلة} - {الفئة: سلسلة} - اقرأ هذه القصة على Magzter.com

يحاول ذهب - حر

"GST reduction makes diagnostics more accessible and supports “Make in India” vision by levelling the field for local products"

BioSpectrum Asia Nov 2025

|

BioSpectrum Asia

The Association of Diagnostics Manufacturers of India (ADMI), the apex body representing 80-90 domestic and multinational in vitro diagnostics (IVD) companies, has announced the election of Jatin Mahajan, Managing Director of J. Mitra & Co., as its new President recently. Under his leadership, ADMI aims to foster greater collaboration between Indian firms and global players through inclusive working groups and open forums. By presenting a unified industry voice, the association plans to engage policymakers and regulators more effectively, advocating for regulatory reforms, quality standards, tax rationalization, and other supportive policies. In an interaction with BioSpectrum Asia Mahajan emphasizes that aligning perspectives across the sector will not only ensure a level playing field but also drive sustainable growth, strengthen India's diagnostics ecosystem, and enhance its global competitiveness. Edited excerpts;

- Sanjiv Das

"GST reduction makes diagnostics more accessible and supports “Make in India” vision by levelling the field for local products"

Being the newly appointed president of the ADMI, how do you foresee the future of India's diagnostic sector?

I am optimistic about the future of India's diagnostic sector. We're at a juncture where diagnostics are rightly being recognised as a cornerstone of healthcare. In the coming years, I see India becoming a global hub for affordable, high-quality diagnostics. Our industry is growing at a double-digit rate, and I anticipate that momentum will continue. More Indian companies will move up the value chain - not just making basic kits, but developing sophisticated molecular diagnostics, AI-driven testing tools, and even exporting lab automation systems. The Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) will catalyse increased spending on R&D, and we anticipate the resultant positive outcomes in the years to come. With initiatives like the PLI scheme creating “global champion” IVD firms out of India, we will have a stronger manufacturing base and innovation pipeline.

Domestically, diagnostics will penetrate deeper: I expect a laboratory or point-of-care facility in every small town, enabled by cost-effective tech developed here. From a global perspective, India's reputation as an exporter of reliable diagnostic products will be solidified – we're already seeing our export growth outpace imports. This trend should enable us to become net exporters by the end of the decade. As ADMI President, I plan to push for all the necessary enablers to realise this vision. The future is one where Indian-developed diagnostic tests and devices are used worldwide, and every citizen has access to timely and accurate tests at home. In short, the outlook is of robust growth and innovation, with India's diagnostics sector attaining a position of global leadership while saving millions of lives through early and precise disease detection.

How big and diverse is the IVD market in India?

المزيد من القصص من BioSpectrum Asia

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Royalty Pharma on-boards Kenneth Sun as Senior Vice President and Head of Asia

US-based Royalty Pharma ple has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Waters launches omniDAWN Multi-Angle Light Scattering (MALS) Photometer

US-based Waters Corporation has announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

South Korea's Cell and Gene Therapy Surge

South Korea's cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.

time to read

5 mins

BioSpectrum Asia May 2026

Listen

Translate

Share

-
+

Change font size